title: Central administration of somatostatin stimulates feeding behavior in chicks.
abstract: The purpose of the present study was to determine if central administration of somatostatin influences feeding behavior in layer chicks. Five- to 7-day-old chicks that received intracerebroventricular (ICV) injections of 0.5 or 2 nmol somatostatin increased their food intake at 30 and 60 min after the injection, suggesting that central somatostatin serves as an orexigenic neuropeptide in chicks. This hypothesis was further supported since chicks ICV injected with 0.5 or 2 nmol cortistatin, which binds to somatostatin receptors, also had increased food intake at the same time. Somatostatin-associated feeding behavior was attenuated by co-administration of 20 nmol beta-funaltrexamine (an opioidergic mu-receptor antagonist) (to 31% of the orexigenic effect of somatostatin at 60 min after the injection) but not ICI-174,864 or nor-binaltorphimine (antagonists of opioidergic delta- and kappa-receptors, respectively). Co-administration of 13 nmol yohimbine, an adrenergic alpha-2 receptor antagonist, also attenuated the orexigenic effect of somatostatin (to 31% of the orexigenic effect of somatostatin at 60 min after the injection). These results suggest that somatostatin-associated feeding behavior is mediated by opioidergic mu- and adrenergic alpha-2-receptors in chicks.
authors.affiliation: Department of Agrobiological Science, Faculty of Agriculture, Ehime University, Matsuyama 790-8566, Japan.
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Tachibana
authors.forename: Mark A
authors.initials: MA
authors.lastname: Cline
authors.forename: Kunio
authors.initials: K
authors.lastname: Sugahara
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ueda
authors.forename: Kohzy
authors.initials: K
authors.lastname: Hiramatsu
mesh_terms: D000477:Alkylating Agents / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D002645:Chickens / Q000502:physiology*; D004435:Eating / Q000187:drug effects*; D004743:Enkephalin, Leucine / Q000031:analogs & derivatives / Q000494:pharmacology; D006728:Hormones / Q000494:pharmacology*; D008297:Male; D009271:Naltrexone / Q000031:analogs & derivatives / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D009479:Neuropeptides / Q000008:administration & dosage / Q000494:pharmacology; D011957:Receptors, Opioid / Q000378:metabolism; D013004:Somatostatin / Q000494:pharmacology*
chemical_list: D000477:Alkylating Agents; D006728:Hormones; D009292:Narcotic Antagonists; D009479:Neuropeptides; D011957:Receptors, Opioid; C099323:cortistatin; C051844:norbinaltorphimine; D013004:Somatostatin; D004743:Enkephalin, Leucine; D009271:Naltrexone; C024524:beta-funaltrexamine; C040643:N,N-diallyl-tyrosyl-alpha-aminoisobutyric acid-phenylalanyl-leucine